TELA Bio, Inc. (TELA) Research

Operating as a commercial-stage medical technology firm, TELA Bio, Inc. is dedicated to improving patient outcomes through advanced soft-tissue reconstruction solutions. Their approach emphasizes the preservation and restoration of the body's natural anatomy. The company offers a diverse portfolio of specialized products, including their flagship OviTex Reinforced Tissue Matrix, extensively utilized for hernia repair and abdominal wall reconstruction. Additionally, OviTex PRS Reinforced Tissue Matrix products cater to specific requirements within plastic and reconstructive surgery, addressing current gaps in treatment. They also provide a specialized OviTex variant designed for laparoscopic and robotic procedures. This sterile, reinforced tissue matrix is derived from ovine rumen and strengthened with polypropylene fiber, specifically engineered for use in minimally invasive hernia repairs. TELA Bio distributes its offerings primarily within the United States, utilizing a dedicated direct sales team. Established in 2012, TELA Bio, Inc. is headquartered in Malvern, Pennsylvania.

Open TELA Bio, Inc. (TELA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.